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Background: Low nuclear expression of the RNA-binding motif protein 3 (RBM3) has previously been found to be
associated with poor prognosis in several cancer forms e.g. breast, ovarian, colorectal, prostate cancer and
malignant melanoma. The aim of this study was to examine the prognostic impact of RBM3 expression in urinary
bladder cancer.
Methods: Immunohistochemical RBM3 expression was examined in tumours from 343 patients with urothelial
bladder cancer. Chi-square and Spearman’s correlation tests were applied to explore associations between RBM3
expression and clinicopathological characteristics. The impact of RBM3 expression on disease-specific survival (DSS),
5-year overall survival (OS) and progression-free survival (PFS) was assessed by Kaplan-Meier analysis and Cox
proportional hazards modelling.
Results: Reduced nuclear RBM3 expression was significantly associated with more advanced tumour (T) stage
(p <0.001) and high grade tumours (p=0.004). Negative RBM3 expression was associated with a significantly shorter
DSS (HR=2.55; 95% CI 1.68-3.86)) and 5-year OS (HR=2.10; 95% CI 1.56-2.82), also in multivariable analysis (HR=1.65;
95% CI 1.07-2.53 for DSS and HR=1.54; 95% CI 1.13-2.10 for 5-year OS). In patients with Ta and T1 tumours expressing
reduced RBM3 levels, Kaplan-Meier analysis revealed a significantly shorter PFS (p=0.048) and 5-year OS (p=0.006).
Conclusion: Loss of RBM3 expression is associated with clinically more aggressive tumours and an independent factor
of poor prognosis in patients with urothelial bladder cancer and a potentially useful biomarker for treatment
stratification and surveillance of disease progression.
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Approximately 20% of patients with urothelial carcin-
oma of the bladder present with muscle invasive cancer
[1]. However, the majority of bladder malignancies do
not invade muscle at diagnosis (Tis, Ta, and T1). The
clinical problem associated with these tumors is their
highly unpredictable potential for recurrence and pro-
gression into muscle invasive disease [1]. High-grade
bladder tumors with lamina propria invasion (T1) repre-
sent those at the greatest risk, rendering the surgical* Correspondence: karolina.boman@med.lu.se
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reproduction in any medium, provided the ormanagement of this disease subject to much controversy
[2]. Nearly one-third of these patients will require cyst-
ectomy as a second-line treatment after failure of
Bacillus Calmette-Guerin (BCG) treatment [3]. The chal-
lenge is to identify these high-risk cases upfront, to offer
them cystectomy as primary treatment. For patients with
muscle-invasive bladder cancer, cystectomy with pelvic
lymph node dissection remains the mainstay of treat-
ment. Overall, approximately 50% of these patients will
develop distant metastases after surgical treatment and
die of the disease [4]. The prognosis worsens for patients
with tumours involving perivesical fat or adjacent organs
(cT3b-4) and those with lymph node involvement. In
these patients, cystectomy alone offers a cure rate ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prognostic and treatment predictive biomarkers to im-
prove clinical management of patients with urothelial
bladder cancer.
Reduced expression of the RNA-binding motif protein
3 (RBM3) has previously been demonstrated to correlate
with an impaired prognosis in several major human can-
cer forms i.e. breast, ovarian, prostate, colorectal cancer
and malignant melanoma [6-10]. While the functional
basis for these observations remain to be fully eluci-
dated, the observed association between RBM3 expres-
sion and DNA integrity and repair [10,11] may be of
importance.
In the present study, we examined the prognostic sig-
nificance of RBM3 expression in tumours from a large
prospective cohort of patients with urothelial bladder
cancer.Table 1 Distribution of patient and tumour characteristics






























All patients with newly diagnosed urothelial bladder
cancer at Uppsala University Hospital have been regis-
tered prospectively since 1984. This study included pa-
tients diagnosed up until 2005 for whom histological
specimens were available. Since the majority of tumoursFigure 1 Sample immunohistochemical images of RBM 3
staining in urothelial bladder cancer. Images (20x magnification)
representing (a) negative, (b) intermediate and (c) high nuclear
RBM3 expression.
Table 2 Associations between RBM3 expression and clinicopathological characteristics.
RBM3 expression Negative (NS=0) Intermediate (NS=1-6) High(NS=9)
n(%) 77 (22.4) 213 (62.1) 53 (15.5) p-value
Age
≤ average 24 (31.2) 107 (50.2) 27 (50.9) 0.013
>average 53 (68.8) 106 (59.8) 26 (49.1)
Gender
Female 26 (33.8) 45 (21.1) 12 (22.6) 0.092
Male 51 (66.2) 168 (78.9) 41 (77.4)
T-stage
Ta 18 (23.4) 74 (34.7) 23 (43.4) <0.001
T1 15 (19.5) 77 (36.2) 24 (45.3)
T2-4 44 (57.1) 62 (29.1) 6 (11.3)
Grade
Low 8 (10.4%) 58 (27.2) 16 (30.2) 0.004
High 69 (89.6%) 155 (72.8) 37 (69.8)
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include 115 tumours. Patient and tumour characteristics
are summarised in Table 1. Progression-free survival
(PFS), overall survival (OS) and disease-specific survival
(DSS) were calculated from the date of surgery to date
of event or last follow-up. At follow up, patients with
non-muscle invasive tumours were categorized as having
none, few or frequent recurrences. Definition of few re-
currences was less than three recurrent tumours within
18 months, whereas frequent recurrences were three or
more recurrences within the same time period. Progres-
sion was defined as shift of the tumor into a higher
stage. Median time to progression for patients with
non-muscle invasive disease was 18.0 months (range
2.0-55.0). Follow-up time for non-recurrent and non-
progressing cases were ≥4 and ≥5-years, respectively.
Tissue microarray construction
The use of these patient samples for protein profiling
was approved by the regional ethical review board of
Uppsala (reference number 2005:339). All tumours were
histopathologically re-evaluated and classified according
to the WHO grading system of 2004 [12] by a board
certified pathologist. Tissue microarrays (TMAs) were
constructed using a semi-automated arraying device
(TMArrayer, Pathology Devices, Westminister, MD,
USA). All tumour samples were represented in duplicate
tissue cores (1mm).
Immunohistochemistry and staining evaluation
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT Link system
and then stained in an Autostainer Plus (DAKO; Glostrup,
Copenhagen, Denmark) with the mouse monoclonal anti-RBM3 antibody AAb030038 (Atlas Antibodies AB,
Stockholm, Sweden) diluted 1:10000. The specificity of the
antibody has been validated previously [6,10], also in the
human bladder cancer cell line RT-4, in which RBM3 was
demonstrated to be highly expressed [6]. RBM3 staining
was evaluated by two independent observers (KB and KJ)
who were blinded to clinical and outcome data. RBM3
was mainly expressed in the nuclei and the fraction of
cells with nuclear positivity (NF) denoted as 0 (0-1%),
1 (2-25%), 2 (26-75%), 3 (>75%), and the intensity of stain-
ing (NI) as 0 (negative), 1 (weak), 2 (moderate) and 3
(strong). The fraction of positively staining cells was esti-
mated across both sampled cores, and the dominating
staining intensity denoted. A combined nuclear score
(NS), e.g. multiplier of NF × NI, was then constructed as
previously described [9,10].
Statistics
Spearman’s rho and Chi-square tests were applied for
analysis of the correlation between RBM3 expression
and clinicopathological characteristics. Kaplan-Meier
analysis and log rank test were used to illustrate differ-
ences in progression free survival (PFS), disease-specific
survival (DSS), overall survival (OS) and 5-year OS in
strata according to RBM3 expression. For survival ana-
lyses, RBM3 expression was trichotomized into negative
(NS=0), intermediate (NS=1-6) and high (NS=9), or
dichotomised into negative (NS=0) vs positive (NS≥1) or
negative-intermediate (NS 0–6) versus high (NS=9). Cox
regression proportional hazards modelling was used to
estimate the impact of negative vs positive RBM3 ex-
pression on DSS, 5-year OS, PFS in both univariable and
multivariable analysis, adjusted for age, sex, T-stage and
grade. All tests were two sided. A p-value of 0.05 was
Figure 2 Kaplan-Meier estimates of bladder cancer specific
survival and 5-year overall survival in the full cohort.
Kaplan-Meier analysis of (a) bladder cancer specific and (b) overall
survival in strata of negative, intermediate and high RBM3
expression.
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performed using IBM SPSS Statistics version 20.0 (SPSS
Inc., Chicago, IL, USA).
Results
Associations between RBM3 expression, patient and
tumour characteristics
Following antibody optimisation and staining, RBM3 ex-
pression could be evaluated in tumours from 343/344
(99,7%) cases. There was no obvious heterogeneity in
RBM3 expression between duplicate TMA cores. Nega-
tive RBM3 staining (NS=0) was denoted in 77 (22.4%)
cases, weak-strong intensity in <75% of the cells (NS 1–
6) in 213 (62.1%) cases and strong staining in > 75% of
the cells (NS=9) was denoted in 53 (15.5%) cases. Het-
erogeneity regarding the nuclear staining fraction be-
tween duplicate cores was only observed in some cases
with intermediate RBM3 expression, and never exceed-
ing 1 category. Images representing different patterns of
RBM expression are shown in Figure 1a-c.
We examined the relationship between three categor-
ies of RBM3 expression; negative (NS=0), intermediate
(NS=1-6) and high (NS=9), and established clinicopatho-
logical parameters (Table 2). This revealed a significant
positive association between RBM3 expression and a
younger age at diagnosis (p=0.013), lower T-stage
(p<0.001) and high grade tumours (p=0.004).
Association between RBM3 expression and survival in the
full cohort
Kaplan-Meier analysis and log-rank test revealed a step-
wise reduced DSS (Figure 2a) and 5-year OS (Figure 2b)
with decreasing RBM3 expression, with the shortest DSS
(p<0.001) and 5-year OS (p<0.001) for patients with
tumours lacking RBM3 expression. These associations
were confirmed in Cox univariable analysis (HR=2.55;
95% CI 1.68-3.86 for DSS and HR=2.10; 95% CI 1.56-
2.82 for 5-year OS) and remained significant in multivar-
iable analysis adjusted for age, gender, T-stage and grade
(HR=1.65; 95% CI 1.07-2.53 for DSS and HR=1.54; 95%
CI 1.13-2.10 for 5-year OS) (Table 3). Separate analysis
of categories of nuclear fraction and staining inten-
sity yielded similar results for DSS and 5-year OS
(Additional file 1).
Association between RBM3 expression, disease
progression and survival in patients with Ta and T1
tumours
Next, we examined the association between RBM3 ex-
pression, disease progression within 24 months and
5-year OS in patients with Ta and T1 tumours. Kaplan-
Meier analysis using three categories of RBM3 expres-
sion revealed a significantly reduced PFS for patients
with RBM3 negative tumours compared to tumours withhigh RBM3 expression (p=0.030). A similarly reduced,
borderline significant, PFS was demonstrated for tu-
mours with intermediate RBM3 expression (Figure 3a),
and when a dichotomised variable of high versus nega-
tive/intermediate RBM3 expression was applied, a sig-
nificantly reduced PFS was seen for the latter category
(p=0.048, Figure 3b). Analysis of 5-year OS using the
trichotomised variable of RBM3 expression (Figure 3c)
Table 3 Relative risks of death from disease and overall death within 5 years according to clinicopathological factors
and RBM3 expression in all patients (n=343)
Risk of death from disease Risk of death within 5 years
Univariable Multivariable Univariable Multivariable
n (events) HR (95% CI) HR (95% CI) n (events) HR (95% CI) HR (95% CI)
Age
Continuous 299 (100) 1.05 (1.03-1.07) 1.04 (1.02-1.07) 343 (123) 1.07 (1.05-1.08) 1.07 (1.05-1.08)
Gender
Female 72 (28) 1.00 1.00 83 (56) 1.00 1.00
Male 227 (72) 0.79 (0.51-1.23) 1.07 (0.68-1.67) 260 (167) 0.95 (0.70-1.29) 1.24 (0.91-1.70)
Stage
Ta 104 (13) 1.00 1.00 115 (61) 1,00 1.00
T1 97 (25) 2.20 (1.13-4.31) 1.87 (0.85-4.08) 116 (71) 1.37 (0.97-1.94) 1.44 (0.96-2.15)
T2-4 99 (62) 8.86 (4.86-16.16) 6.77 (3.21-14.26) 112 (91) 2.79 (2.01-3.87) 2.90 (1.92-4.40)
Grade
Low 75 (7) 1.00 1.00 82 (41) 1.00 1.00
High 224 (93) 5.75 (2.66-12.40) 1.52 (1.58-3.96) 261 (182) 2.04 (1.45-2.87) 0.90 (0.58-1.39)
RBM3 expression
Positive 232 (66) 1.00 1.00 266 (160) 1.00 1.00
Negative 67 (34) 2.55 (1.68-3.86) 1.65 (1.07-2.53) 77 (63) 2.10 (1.56-2.82) 1.54 (1.13—2.10)
Boman et al. BMC Urology 2013, 13:17 Page 5 of 8
http://www.biomedcentral.com/1471-2490/13/17revealed a significantly reduced survival for patients with
RBM3 negative tumours compared to those with high
expression (p=0.005) while survival was similar for the
intermediate category for RMB3 expression, as also
demonstrated using a dichotomised variable comparing
negative RBM3 expression with any RBM3 expression
(p=0.006, Figure 3d).
Cox regression analysis demonstrated that neither RBM3
expression nor any of the established clinicopathological
factors were significantly associated with PFS, but that
grade and RBM3 expression (negative-intermediate vs high)
were the best predictors of disease progression within 24
months in both univariable and multivariable analysis
(Table 4). However, a significantly shorter 5-year OS was
seen for RBM3 negative compared to RBM3 positive
tumours in univariable analysis (n=231; HR=2.00 95%
CI 1.21-3.33) and borderline significant in multivariable
analysis (HR=1.64 95% CI 0.96-2.78) (Table 4). There was a
borderline significant association between RMB3 expres-
sion and DSS in both univariable analysis (n=201; HR=3.06
95% CI 0.95-10.00) and multivariable analysis (n=201;
HR=3.24 95% CI 1.00-10.53). There was no significant asso-
ciation between RBM3 expression and the rate of recur-
rence (none, few or frequent) (data not shown).
Similar findings were seen in subgroup analysis of pa-
tients with T1 tumours, where none of the patients with tu-
mours expressing high levels of RMB3 (n=14) had disease
progression during 24 months follow-up, in contrast to tu-
mours with intermediate and negative expression (n= 52,
12 events) (data not shown). In patients with T1 tumours, asignificant correlation was seen between negative RBM3
expression and a reduced 5-year OS in both univariable
analysis (n=116; HR=2.44 95% CI 1.25-4.75) and multivari-
able analysis (HR=1.98 95% CI 1.01-3.90).
Discussion
The results from this study show that reduced RBM3 ex-
pression is significantly associated with more aggressive
tumours and an independent predictor of reduced sur-
vival in patients with urothelial bladder cancer. More-
over, in patients with Ta and T1 tumours, reduced
RBM3 expression correlated with a significantly shorter
time to disease progression, despite the comparatively
low number of events, and negative RBM3 expression
was an independent predictor of a reduced 5-year overall
survival. The association between RBM3 expression and
a favorable clinical outcome has been demonstrated in
several other cancer forms [6-10] but this is, to our
knowledge, the first report of the prognostic impact of
RBM3 expression in urothelial bladder cancer.
In this comparatively large study of retrospectively col-
lected tumours from a prospective cohort of patients with
urothelial bladder cancer, the most evident impact of
RBM3 expression was seen for disease specific and overall
survival, both in the full cohort and in subgroup analysis
of patients with Ta and T1 tumours. The fact that the im-
pact on progression-free survival in patients with Ta and
T1 tumours was not as significant may be due to the
lower number of events, and therefore, the association be-
tween RBM3 expression and tumour progression merits
Figure 3 Kaplan-Meier estimates of progression free survival and 5-year overall survival in patients with Ta and T1 tumours.
Kaplan-Meier analysis of progression free survival in strata according to (a) negative, intermediate and high RBM3 expression and (b) negative-
intermediate versus high expression, and 5-year overall survival in (c) negative, intermediate and high RBM3 expression and (d) negative versus
positive expression.
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pression was not associated with neither occurrence nor
frequency of local recurrence. These findings may indeed
indicate different, or even opposing, tumour biological
roles for RBM3 in tumour initiation and progression of
urothelial bladder cancer. Previous studies, e.g. in malig-
nant melanoma, have demonstrated that the correlation
between reduced RBM3 expression and overall survival
was more evident than the correlation to recurrent disease
[8]. Speculatively, these findings could indicate that loss of
RBM3 expression results in a tumour phenotype more
prone to metastatic spread than local aggressiveness.
RBM3 has previously been shown to be upregulated in
neoplastic as compared to normal tissue [7,9], which
also seems to be true for urothelial bladder epithelium
versus urothelial neoplasms (www.proteinatlas.org). While
urothelial bladder cancer is in its nature a recurrentdisease [1], a recurrence does not per se affect survival
from the disease. It is therefore plausible to assume that
tumours with high RBM3 expression may well recur, while
loss of RBM3 expression will generate a disease more
likely to muscle invasion and distant spread.
The precise functional mechanisms behind loss of RBM3
and a more aggressive tumour behaviour remain to be elu-
cidated. However, in vitro models need to be designed and
interpreted with the impact of RBM3 expression on clinical
outcome in mind, and the previously demonstrated pro-
tumourigenic properties for RBM3 in vitro, e.g. that siRNA
mediated silencing of the gene renders cancer cells less pro-
liferative [10,13,14], should not be interpreted as being
contradictory to its association with a prolonged survival
when expressed in human tumours.
In a translational context, further probing of the asso-
ciation between RBM3 and DNA integrity and repair,
Table 4 Relative risks of progression within 24 months and overall death within 5 years according to
clinicopathological factors and RBM3 expression in patients with Ta and T1 tumours
Risk of progression within 24 months Risk of death within 5 years
Univariable Multivariable Univariable Multivariable
n(events) HR(95%CI) HR(95%CI) n(events) HR(95%CI) HR(95%CI)
Age
Continuous 134(19) 1.02(0.98-1.07) 1.01(0.97-1.06) 231(88) 1.06(1.04-1.09) 1.06(1.04-1.08)
Gender
Female 29(2) 1.00 1.00 43(12) 1.00 1.00
Male 105(17) 2.48(0.57-10.74) 1.98(0.45-8.64) 188(76) 0.62(0.34-1.13) 1.67(0.90-3.10)
Grade
Low 48(3) 1.00 1.00 81(19) 1.00 1.00
High 86(16) 3.24(0.94-11.12) 3.32(0.97-11.40) 150(69) 2.22(1.33-3.68) 1.31(0.73-2.35)
Stage
Ta 68(7) 1.00 1.00 115(35) 1.00 1.00
T1 66(12) 1.90(0.75-4.83) 1.24(0.44-3.46) 116(53) 0.61(0.40-0.93) 1.61(1.04-2.49)
RBM3 expression* RBM3 expression*
High 31(1) 1.00 1.00 Positive 198(69) 1.00 1.00
Negative/Intermediate 103(18) 5.92(0.79-44.39) 6.10(0.81-45.69) Negative 33(19) 2.00(1.21-3.33) 1.64(0.96-2.78)
For PFS a dichotomised variable comparing patients with negative or intermediate RBM3 expression to those with high expression was applied. For 5 year OS, a
dichotomised variable of negative versus any RBM3 expression was applied.
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in vivo and in vitro [11], may give more insight into
the mechanistic basis for the favourable prognostic im-
pact of RBM3 expression, once a tumour has been
established. The link between RBM3 expression and an
attenuated DNA damage response not only fits with its
previously demonstrated association with cisplatin sensi-
tivity , but also its association with good prognosis, since
a deficient DNA repair system may well decrease the
capability of invasion and metastatic spread [15,16].
Along this line, it would also be of interest to investigate
the impact of RBM3 as a predictor of response to
platinum-based chemotherapy, both in the neoadjuvant,
adjuvant and palliative setting, cisplatin being one of the
cornerstones in the medical treatment of bladder cancer
[17-20]. Few molecular markers have proven to be effi-
cient predictors of treament response, and none have
been incorporated into clinical protocols. The question
of the role of RBM3 as a marker for platinum sensitivity
could not be addressed in the present study, as treat-
ment data was lacking for the majority of the patients.
The clinical management of urothelial bladder cancer
holds room for improvement. The monitoring is not only
troublesome for the patients, but is also costly for the
health care system. In fact, due to its high rate of recur-
rence and invasive monitoring requirements, urothelial
bladder cancer has the highest lifetime treatment cost per
patient of all cancers in the United States [21]. Hence, the
benefit of finding tools to better identify patients more
likely to have, or being at risk of developing, muscleinvasive and metastatic desease is evident. Here, we have
demonstrated a stepwise reduced survival with decreasing
levels of nuclear RBM3 expression. While the greatest im-
pact on DSS and OS was seen for patients with tumours
lacking RBM3 expression, an increased risk of disease pro-
gression was also observed in the patient group with inter-
mediate expression. This observation, together with the
strong correlation between loss of RBM3 and muscle inva-
sive disease, indicates that loss of RBM3 expression may
indeed be a marker of disease progression. Therefore, im-
munohistochemical assessment of RBM3 expression could
prove to be a valuable tool to more accurately predict
muscle invasion, even in suboptimal samples from trans-
urethral resections of the bladder. Moreover, it would be
of interest to evaluate whether immunocytochemical
RBM3 expression could be a useful diagnostic tool for
urine cytology samples, to distinguish between different
low-grade urothelial neoplastic lesions, e.g. papillary
neoplasms of low malignant potential and low-grade pap-
illary urothelial carcinomas, entities with considerable
cytologic-histologic discrepancies [22]. While the findings
in the present study are based on analyses of transitional
cell carcinoma, it would also be of interest to examine
RBM3 expression and its possible prognostic implications
in other histological subtypes of bladder cancer, e.g. squa-
mous cell carcinoma or adenocarcinoma.
Conclusions
The results from this study suggest that immunohisto-
chemical evaluation of RBM3 expression in urothelial
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prognostic biomarker, and a useful tool for improved treat-
ment stratification of patients suffering from the disease.
Additional file
Additional file 1: Prognostic value of categories of nuclear fcation
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<0.001 for all).
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